EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary

Leon A Adams, William W Kemp, Kate R Muller, Elizabeth E Powell, Stuart K Roberts iD, Luis Calzadilla Bertot iD, Stephanie Best, Gary Deed iD, Jon D Emery iD, Samantha L Hocking, Graham R Jones, John S Lubel und 4 weitere

Medical Journal of Australia · 2025

DOI: 10.5694/mja2.70008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Journal of Australia, 2025. Verfasst von Leon A Adams und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Western Australia, Perth, WA. Hauptthemen laut MEDLINE: Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gastroenterological Society of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Metabolic dysfunction‐associated fatty liver disease (MAFLD) is common. This evidence‐based consensus statement summary provides recommendations for the assessment and monitoring of adults with MAFLD in primary care. Main recommendations Adults with type 2 diabetes, obesity or two or more other metabolic risk factors should be tested for MAFLD. Hepatic steatosis should be evaluated using ultrasound, whereas the presence and complications of type 2 diabetes and obesity should be assessed according to current Australian guidelines. Cardiovascular disease, chronic kidney disease and obstructive sleep apnoea are common in people with MAFLD and should be considered as part of a holistic health assessment. Alternative causes of hepatic steatosis, including excess alcohol consumption, must be considered, and patients with elevated serum aminotransferase levels should be tested for hepatitis B and C infection and iron overload. The risk of advanced liver fibrosis requires assessment using the Fibrosis‐4 (FIB‐4) Index; a low score (< 1.3) is associated with a more than 95% negative predictive value for advanced liver fibrosis. People with an indeterminate FIB‐4 score (between 1.3 and 2.7) should undergo second‐line assessment with liver elastography or a direct liver fibrosis serum test or, if these tests are unavailable, should be referred to an expert clinician in liver disease. People with MAFLD and a high FIB‐4 score (> 2.7), an elevated direct liver fibrosis serum test, high elastography results or with clinical, laboratory or imaging evidence of cirrhosis should be referred for further evaluation. Individuals with a low FIB‐4 score (< 1.3), low elastography or direct liver fibrosis serum test results should be monitored with a repeat FIB‐4 test at least every three years. Monitoring of weight, body mass index and/or waist circumference and for emergence of type 2 diabetes (in individuals without) should be performed at least annually. Change in management as a result of this consensus statement summary Appropriate identification, assessment and risk stratification of people with MAFLD will aid referral pathways, further investigation and management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverNon-alcoholic Fatty Liver DiseaseHumansPrimary Health CareDiabetes Mellitus, Type 2AustraliaRisk FactorsObesityLiver CirrhosisAdult

Stichwörter der Autor:innen

Diabetes mellitus, type 2Liver cirrhosisLiver diseasesObesityPrimary careReferral and consultationRisk assessmentUltrasonography

Autor:innen und Institutionen

  • University of Western Australia, Perth, WA.
  • Sir Charles Gairdner Hospital, Perth, WA.
  • Alfred Health, Melbourne, VIC.
  • Flinders Medical Centre, Adelaide, SA.
  • Princess Alexandra Hospital, Adelaide, SA.
  • QIMR Berghofer Medical Research Institute, Brisbane, QLD.

ORCID-Profile: Stuart K Roberts, Luis Calzadilla Bertot, Gary Deed, Jon D Emery, Jacob George

Förderung

  • Gastroenterological Society of Australia

Zitieren

APA

Adams, L. A., Kemp, W. W., Muller, K. R., Powell, E. E., Roberts, S. K., Bertot, L. C., Best, S., Deed, G., Emery, J. D., Hocking, S. L., Jones, G. R., Lubel, J. S., Sheils, S., Twigg, S. M., Watts, G. F., & George, J. (2025). Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary. Medical Journal of Australia. https://doi.org/10.5694/mja2.70008

Vancouver

Adams LA, Kemp WW, Muller KR, Powell EE, Roberts SK, Bertot LC, et al. Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary. Medical Journal of Australia. 2025. doi:10.5694/mja2.70008

BibTeX
@article{Adams2025,
  author = {Adams, Leon A and Kemp, William W and Muller, Kate R and Powell, Elizabeth E and Roberts, Stuart K and Bertot, Luis Calzadilla and Best, Stephanie and Deed, Gary and Emery, Jon D and Hocking, Samantha L and Jones, Graham R and Lubel, John S and Sheils, Sinead and Twigg, Stephen M and Watts, Gerald F and George, Jacob},
  title = {Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary},
  journal = {Medical Journal of Australia},
  year = {2025},
  doi = {10.5694/mja2.70008}
}
Kostenlos starten →